Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - diphtheria toxoid (d); filamentous haemagglutinin (fha); hib purified capsular polysaccharide; pertactin (prn or 69kda outer membrane protein); pertussis toxoid (pt); polio virus type 1 (inactivated); polio virus type 2 (inactivated); polio virus type 3 (inactivated); tetanus toxoid (t) - injection - min 30iu/0.5ml - diphtheria toxoid (d) min 30iu/0.5ml; filamentous haemagglutinin (fha) 25mcg/0.5ml; hib purified capsular polysaccharide 10 mcg/0.5 ml; pertactin (prn or 69kda outer membrane protein) 8mcg/0.5ml; pertussis toxoid (pt) 25mcg/0.5ml; polio virus type 1 (inactivated) 40du/0.5ml; polio virus type 2 (inactivated) 8du/0.5ml; polio virus type 3 (inactivated) 32du/0.5ml; tetanus toxoid (t) min 40iu/0.5ml

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; fillamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin; pertussis toxoid (pt); tetanus toxoid - powder and suspension for suspension for injection - diphtheria toxoid nlt 60 iu/ml; inactivated polio virus (ipv) type 3 64 du / 1 ml; inactivated polio virus (ipv) type 2 16 du / 1 ml; inactivated polio virus (ipv) type 1 80 du / 1 ml; pertussis toxoid (pt) 50 mcg/ml; fillamentous haemagglutinin (fha) 50 mcg/ml; pertactin 16 mcg/ml; tetanus toxoid nlt 80 iu/ml; haemophilus influenzae type b polysaccharide 20 mcg/vial - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - active immunisation in infants from the age of 2 months to 5 years against diptheria, tetanus, pertussis, poliomyelitis and haemophilus influenza type b. booster dose for children who have previously been immunised with dtp, polio and hib antigens

Malta - English - Medicines Authority

smithkline beecham limited - pertactin; pertussis filamentous haemagglutinin; pertussis toxoid; poliovirus (inactivated) type 1 (mahoney strain); poliovirus (inactivated) type 2 (mef-1 strain); poliovirus (inactivated) type 3 (saukett strain); diphtheria toxoid; haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate); tetanus toxoid - powder and suspension for suspension for injection - pertactin 8 µg; pertussis filamentous haemagglutinin 25 µg; pertussis toxoid 25 µg; poliovirus (inactivated) type 1 (mahoney strain) 40 dagu/0.5ml; poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu/0.5ml; poliovirus (inactivated) type 3 (saukett strain) 32 dagu/0.5ml; diphtheria toxoid; haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 10 µg; tetanus toxoid - vaccines

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - pertactin, pertussis toxoid, poliovirus, inactivated, type, mahoney strain, mef, saukett strain, diphtheria toxoid, filamentous haemagglutinin, fha, fimbriae types, and, haemophilus influenzae, type b, polysaccharide, polyribosylribitol phosphate, tetanus toxoid - suspension for injection in pre-filled syringe - pertactin 3 µg pertussis toxoid 20 µg poliovirus (inactivated) type 1 (mahoney strain) 40 dagu poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu poliovirus (inactivated) type 3 (saukett strain) 32 dagu diphtheria toxoid filamentous haemagglutinin (fha) 20 µg fimbriae types 2 and 3 5 µg haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 10 µg tetanus toxoid - vaccines

Canada - English - Health Canada

sanofi pasteur limited - pertussis toxoid; filamentous haemagglutinin; fimbriae; pertactin; diphtheria toxoid; tetanus toxoid; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett; haemophilus influenzae type b-prp; tetanus protein - liquid - 20mcg; 20mcg; 5mcg; 3mcg; 15lf; 5lf; 40unit; 8unit; 32unit; 10mcg; 30mcg - pertussis toxoid 20mcg; filamentous haemagglutinin 20mcg; fimbriae 5mcg; pertactin 3mcg; diphtheria toxoid 15lf; tetanus toxoid 5lf; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40unit; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8unit; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32unit; haemophilus influenzae type b-prp 10mcg; tetanus protein 30mcg - vaccines

Canada - English - Health Canada

sanofi pasteur limited - pertactin; pertussis toxoid; diphtheria toxoid; tetanus toxoid; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett; haemophilus influenzae type b-prp; tetanus protein; filamentous haemagglutinin; fimbriae - suspension - 3mcg; 20mcg; 15lf; 5lf; 29unit; 7unit; 26unit; 10mcg; 30mcg; 20mcg; 5mcg - pertactin 3mcg; pertussis toxoid 20mcg; diphtheria toxoid 15lf; tetanus toxoid 5lf; inactivated poliomyelitis vaccine (v.c.o.) type 1 mahoney 29unit; inactivated poliomyelitis vaccine (v.c.o.) type 2 mef1 7unit; inactivated poliomyelitis vaccine (v.c.o.) type 3 saukett 26unit; haemophilus influenzae type b-prp 10mcg; tetanus protein 30mcg; filamentous haemagglutinin 20mcg; fimbriae 5mcg - vaccines

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi pasteur msd ltd - human poliovirus type 3 inactivated; tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; diphtheria toxoid; haemophilus influenzae type b polysaccharide protein conjugate - suspension for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - diphtheria toxoid; tetanus toxoid; pertussis antigens; human poliovirus type 1 inactivated; human poliovirus type 2 inactivated; human poliovirus type 3 inactivated; haemophilus influenzae type b polysaccharide protein conjugate - powder and suspension for suspension for injection

Malta - English - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - pertactin, pertussis filamentous, haemagglutinin, pertussis toxoid, poliovirus, inactivated, type, mahoney strain, mef, saukett strain, diphtheria toxoid, haemophilus influenzae, type b, polysaccharide, polyribosylribitol phosphate, tetanus toxoid - powder and suspension for suspension for injection - pertactin 8 µg pertussis filamentous haemagglutinin 25 µg pertussis toxoid 25 µg poliovirus (inactivated) type 1 (mahoney strain) 40 dagu/0.5ml poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu/0.5ml poliovirus (inactivated) type 3 (saukett strain) 32 dagu/0.5ml diphtheria toxoid haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 10 µg tetanus toxoid - vaccines

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - (prefilled syringe) diphtheria toxoid; (prefilled syringe) filamentous haemagglutinin; (prefilled syringe) pertussis toxoid; (prefilled syringe) poliovirus (inactivated) - type 1 (mahoney); (prefilled syringe) poliovirus (inactivated) - type 2 (mef-1); (prefilled syringe) poliovirus (inactivated) - type 3 (saukett); (prefilled syringe) tetanus toxoid; (vial) haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein; (vial) tetanus protein (prp-t) - injection, powder, for suspension - (prefilled syringe) diphtheria toxoid min. 20 iu (30 lf)/0.5 ml; (prefilled syringe) filamentous haemagglutinin 25 μg/0.5 ml; (prefilled syringe) pertussis toxoid 25 μg/0.5 ml; (prefilled syringe) poliovirus (inactivated) - type 1 (mahoney) 40 du/0.5 ml; (prefilled syringe) poliovirus (inactivated) - type 2 (mef-1) 8 du/0.5 ml; (prefilled syringe) poliovirus (inactivated) - type 3 (saukett) 32 du/0.5 ml; (prefilled syringe) tetanus toxoid min. 40 iu (10 lf) /0.5 ml; (vial) haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus protein 10 μg/0.5 ml; (vial) tetanus protein (prp-t) 18 - 30 μg/0.5 ml